Anke Bio: Affiliated company Alpha Biopharma completes first close of $50 million Series A financing

According to Anke Bio, recently, the company's affiliated company Hefei Afna Biotechnology Co., Ltd. announced the completion of the first close of its Series A financing. The total scale of the Series A financing is USD 50 million. The first close was led by Guozhong Capital, with Life Health Company under Hefei Industrial Investment Group, Chantou Guozheng, and Anhui Ceyuan Industrial Investment Co., Ltd. jointly leading the investment, Venture Capital Guidance Fund Company under Hefei Industrial Investment Group making an additional investment, and Nanjing Hongjing, Shenzhen Jiurong, and Shanghai Qinli participating as follow-on investors. This round of financing will mainly be used to accelerate the efficient advancement of Afna Biotechnology's core pipelines such as in vivo CAR-T and tumor vaccines, continuously iterate the TALENT technology platform, and further strengthen the company's comprehensive capabilities in CMC, regulatory development, and industrialization, accelerating the entry of globally competitive innovative therapies into clinical and subsequent development stages.